Late-Breaking Abstract 4 (LBA4),1 presented in the Plenary Session, further expanded our understanding of the role of osimertinib in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.